New functionality puts the power of lesion-specific plaque analysis directly into the physician’s hands, giving deeper insight into coronary and carotid artery disease

Elucid announced today the commercial availability of a new Lesion Inspection Tool for coronary and carotid plaque analysis in its novel Plaque-IQ software suite. The tool provides physicians the ability to interrogate lesion-specific composition and plaque burden across any vessel, which can help the physician better understand the patient risk profile to enhance clinical decision-making.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415111761/en/

Elucid's new Lesion Inspection Tool for coronary and carotid plaque analysis in its Plaque-IQ software suite provides physicians the ability to interrogate lesion-specific composition and plaque burden across any vessel.

“The Lesion Inspection Tool provides a detailed view of plaque composition at the lesion level, beyond giving just overall plaque metrics,” said Jimmy Kerrigan, MD, an interventional cardiologist with Ascension Saint Thomas Heart. “Because cardiovascular events like heart attacks occur at the lesion level, having the ability to characterize individual lesions enhances my understanding of a patient’s disease process and supports more informed clinical decision-making.”

Plaque-IQ’s Lesion Inspection Tool allows users to interrogate any lesion or region, and access quantitative results displayed for the specific segment. By providing precise quantification of plaque types at the lesion level, the tool allows physicians to quantify high-risk features like lipid-rich necrotic core (LRNC). This objective and actionable data supports proactive, individualized treatment strategies.

Elucid’s Plaque-IQ is the only plaque analysis technology trained and validated against objective ground truth histology, the gold standard for plaque characterization. Powered by CT-Virtual Histology™ (CT-VH™), Plaque-IQ noninvasively quantifies and classifies coronary and carotid plaque and its components – including LRNC – offering direct insights into high-risk plaque features associated with heart attack and stroke, measuring true disease rather than directional proxies.

By focusing on true disease biology rather than population-based risk estimates, this approach is designed to help physicians prioritize and personalize treatment for each individual patient.

About Elucid

Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise analysis of atherosclerosis (coronary and carotid plaque buildup), the root cause of cardiovascular disease. The company’s Plaque-IQ™ software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. Plaque-IQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque. Plaque-IQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR_CT, derived from its plaque algorithm, resulting in concordance between plaque and FFR_CT. FFR_CT helps physicians identify coronary blockages and the extent of a patient’s ischemia non-invasively. For more information, visit elucid.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260415111761/en/

By providing precise quantification of plaque types at the lesion level, the tool allows physicians to quantify high-risk features like lipid-rich necrotic core (LRNC).